Medicare Enrolled
Dr. David Marks, M.D.
Pulmonary Disease · San Antonio, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Marks from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marks?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Marks
Dr. David Marks is a pulmonary disease specialist in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Marks performed 5,088 Medicare services across 3,185 unique beneficiaries.
Between the years covered by Open Payments, Dr. Marks received a total of $367,544 from 58 pharmaceutical and/or device companies across 918 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Marks is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in TX
$367,544 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,088
Medicare services
Top 4% in TX for pulmonary disease
3,185
Unique beneficiaries
$71
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~268 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Home visit, established patient, moderate complexity A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service. |
995 | $91 | $450 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
710 | $82 | $286 |
| Home visit, established patient, high complexity A home visit for an established patient involving high-level medical decision making, lasting at least 60 minutes. |
608 | $131 | $639 |
| Blood glucose test using hand-held instrument A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels. |
505 | $3 | $15 |
| Home visit, established patient, low complexity A physician visits an existing patient at their residence to provide care involving a low level of medical decision making. The visit lasts at least 30 minutes. |
401 | $51 | $296 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
350 | $38 | $127 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
348 | $40 | $132 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
267 | $19 | $65 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
136 | $120 | $392 |
| Home visit, new patient, high complexity A home visit for a new patient involving high-level medical decision making, lasting at least 75 minutes. |
123 | $138 | $756 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
102 | $210 | $998 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
95 | $3 | $15 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
88 | $26 | $96 |
| Home visit, new patient, moderate complexity A home visit for a new patient involving moderate medical decision making, lasting at least 60 minutes. |
73 | $101 | $620 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 48 | $20 | $75 |
| COVID-19 immunoassay detection test A laboratory test that uses an immunoassay method to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) through direct visual observation. |
47 | $41 | $350 |
| Home visit, established patient, straightforward decision making A home visit for an established patient involving straightforward medical decision making. The visit lasts at least 15 minutes when time is used to determine the level of service. |
41 | $33 | $194 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
26 | $26 | $81 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
21 | $0 | $52 |
| Psychiatric diagnostic evaluation with medical services A psychiatric assessment that includes medical services to evaluate mental health conditions. |
20 | $151 | $600 |
| Telephone or internet consultation, more than 30 minutes A remote assessment conducted by a consulting physician via telephone or internet, lasting more than 30 minutes and including a verbal and written report. |
20 | $52 | $140 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
20 | $153 | $660 |
| Telephone or internet consultation, 21-30 minutes A remote assessment conducted by a consulting physician via telephone or internet, including verbal discussion and a written report, lasting 21 to 30 minutes. |
18 | $41 | $106 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
13 | $48 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
13 | $0 | $5 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$367,544
Total received (2018-2024)
Avg $52,506/year across 7 years
Top 1% in TX for pulmonary disease
58
Companies
918
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$355,455 (96.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,089 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$163,954
2023
$90,847
2022
$25,017
2021
$28,075
2020
$19,497
2019
$16,641
2018
$23,512
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$296,260
GlaxoSmithKline, LLC.
$35,683
Boehringer Ingelheim Pharmaceuticals, Inc.
$7,890
INTUITIVE SURGICAL, INC.
$6,749
Bayer HealthCare Pharmaceuticals Inc.
$6,529
Mallinckrodt Hospital Products Inc.
$2,803
Inspire Medical Systems, Inc.
$1,955
Actelion Pharmaceuticals US, Inc.
$1,616
Pulmonx Corporation
$879
Hill-Rom Company, Inc
$875
Grifols USA, LLC
$721
BOSTON SCIENTIFIC CORPORATION
$648
Regeneron Healthcare Solutions, Inc.
$416
Merz North America, Inc.
$296
Shire North American Group Inc
$293
Jazz Pharmaceuticals Inc.
$290
Mylan Specialty L.P.
$284
Electromed, Inc.
$227
Takeda Pharmaceuticals U.S.A., Inc.
$218
JAZZ PHARMACEUTICALS INC.
$196
ZOLL Respicardia, Inc.
$161
Mallinckrodt LLC
$161
United Therapeutics Corporation
$159
Sunovion Pharmaceuticals Inc.
$157
Philips Electronics North America Corporation
$149
GENZYME CORPORATION
$144
Becton, Dickinson and Company
$137
Organogenesis Inc.
$130
Vifor Pharma, Inc.
$114
PFIZER INC.
$111
Gilead Sciences, Inc.
$106
BioFire Diagnostics, LLC
$90
Allergan Inc.
$84
Janssen Pharmaceuticals, Inc
$70
Axsome Therapeutics, Inc.
$69
Circassia Pharmaceuticals Inc
$67
Fisher & Paykel Healthcare Inc
$67
Insmed, Inc.
$66
Bayer Healthcare Pharmaceuticals Inc.
$63
Tactile Systems Technology Inc
$63
Baxter Healthcare
$55
Advanced Respiratory, Inc
$54
Amgen Inc.
$50
Phadia US Inc.
$48
Genentech USA, Inc.
$47
Novartis Pharmaceuticals Corporation
$46
Paratek Pharmaceuticals, Inc.
$39
Merck Sharp & Dohme LLC
$29
ANI Pharmaceuticals, Inc.
$23
HARMONY BIOSCIENCES LLC
$22
Circassia Inc.
$22
Itamar Medical Inc
$21
IDORSIA PHARMACEUTICALS US INC
$20
ARBOR PHARMACEUTICALS, INC.
$18
OptiNose US, Inc.
$15
SANOFI-AVENTIS U.S. LLC
$14
Boston Scientific Corporation
$13
Apria Healthcare LLC
$12
Top 3 companies account for 92.5% of total payments
Associated products mentioned in payments ›
(7999) SRC Und · ACTHAR · AIRSUPRA · ALAIR · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · BioFire FilmArray · CHANTIX · CHARTIS CATHETER · CUVITRU · DALIRESP · DUPIXENT · DYNAMIC · Da Vinci Surgical System · ELIQUIS · Esbriet · FASENRA · FISHER & PAYKEL HEALTHCARE · Flexitouch Plus · GENERAL PULMONARY · GLASSIA · Hillrom - Life 2000 Ventilation System · Horizant · INSPIRE · ImmunoCAP · LONHALA MAGNAIR · Life 2000 Ventilation System · Medela · NIOX · NO PRODUCT DISCUSSED · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · Puraply · QUVIVIQ · REMODULIN · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System 205 Acute Care · Trilogy 100 · ULTRAFLEX · UPTRAVI · Utibron · Veltassa · WINREVAIR · Wakix · WatchPAT · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · XYWAV · Xembify · Xhance · Xolair · Xyrem · Yupelri · Zemaira · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (97%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in TX.
Equivalent to $7,224 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
74
Per 100K population
3.6
County median income
$70,571
Nearest hospital
SOUTH TEXAS SPINE AND SURGICAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Marks is a clinical cardiology specialist, with above-average Medicare volume (top 4% in TX), with speaking/promotional industry engagement in the top 1% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Marks experienced with home visit, established patient, moderate complexity?
Based on Medicare claims data, Dr. Marks performed 995 home visit, established patient, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Marks receive payments from pharmaceutical companies?
Yes. Dr. Marks received a total of $367,544 from 58 companies across 918 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marks's costs compare to other pulmonary diseases in San Antonio?
Dr. Marks's average Medicare payment per service is $71. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marks) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in San Antonio
Browse pulmonary diseases in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology